Advertisement

Dermatologic Emergencies

  • Steven R. MaysEmail author
  • Sharon R. Hymes
  • Katherine C. Cole
  • Henry M. Kuerer
Part of the MD Anderson Cancer Care Series book series (MDCCS)

Abstract

Patients present to the emergency rooms at cancer centers with a wide spectrum of skin diseases. These diseases include drug reactions, primary cutaneous infections, inflammatory skin disorders (such as Sweet syndrome), graft-versus-host disease (GVHD), and skin signs of disseminated infections. This chapter covers four skin disorders that each have a high associated morbidity: toxic epidermal necrolysis (TEN), drug hypersensitivity syndrome (now known as drug reaction with eosinophilia and systemic symptoms [DRESS]), necrotizing fasciitis, and cutaneous GVHD. With the exception of GVHD, these disorders occur as frequently in the mildly immunosuppressed host as they do in the severely immunosuppressed.

Keywords

Toxic epidermal necrolysis Drug reaction with eosinophilia and systemic signs Cutaneous graft-versus-host disease Necrotizing fasciitis 

Suggested Readings

  1. Abood GJ, Nickoloff BJ, Gamelli RL. Treatment strategies in toxic epidermal necrolysis syndrome. J Burn Care Res. 2008;29:269–76.PubMedGoogle Scholar
  2. Ang C, Wang Y, Yoosuff E, et al. Retrospective analysis of drug-induced hypersensitivity syndrome: a study of 27 patients. J Am Acad Dermatol. 2010;63:219–27.CrossRefPubMedGoogle Scholar
  3. Ben m’rad M, Leclerc S, Blanche P, et al. Drug-induced hypersensitivity syndrome. Medicine. 2009;88:131–40.CrossRefPubMedGoogle Scholar
  4. Childers BJ, Potyondy LD, Nachreiner R, et al. Necrotizing fasciitis: a fourteen-year retrospective study of 163 consecutive patients. Am Surg. 2002;68:109–16.PubMedGoogle Scholar
  5. Endorf FW, Cancio LC, Gibran NS. Toxic epidermal necrolysis clinical guidelines. J Burn Care Res. 2008;29:706–12.CrossRefPubMedGoogle Scholar
  6. Fromowitz JS, Ramos-Caro F, Flower FP. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol. 2007;46:1092–4.CrossRefPubMedGoogle Scholar
  7. Gerdts B, Vloemans A, Kreis RW. Toxic epidermal necrolysis: 15 years experience in a Dutch burns center. J Eur Acad Dermatol Venereol. 2007;21:781–8.CrossRefPubMedGoogle Scholar
  8. Hebert AA, Bogle MA. Intravenous immunoglobulin for recurrent Stevens-Johnson syndrome. J Am Acad Dermatol. 2004;50:268–88.CrossRefGoogle Scholar
  9. Hymes S, Couriel D. Graft-versus-host disease. In: Yeung S-CJ, Escalante CP, Gagel RF, editors. Medical care of cancer patients. Shelton, CT: B.C. Decker; 2009. p. 578–89.Google Scholar
  10. Hymes SR, Alousi AM, Cowen EW. Graft-versus-host disease: Part I. Pathogenesis and clinical manifestations of graft-versus-host disease. J Am Acad Dermatol. 2012a;66:535.CrossRefPubMedGoogle Scholar
  11. Hymes SR, Alousi AM, Cowen EW. Graft-versus-host disease: Part II. Management of cutaneous graft-versus-host disease. J Am Acad Dermatol. 2012b;66:535.CrossRefPubMedGoogle Scholar
  12. Knowles SR, Shapiro L, Shear NH. Serious adverse reactions induced by minocycline. Arch Dermatol. 1996;132:934–9.CrossRefPubMedGoogle Scholar
  13. Lissia M, Mulas P, Bulla A, et al. Toxic epidermal necrolysis. Burns. 2010;36:152–63.CrossRefPubMedGoogle Scholar
  14. Mok MY, Wong SY, Chan TM, et al. Necrotizing fasciitis in rheumatic diseases. Lupus. 2006;15:380–3.CrossRefPubMedGoogle Scholar
  15. Nigen S, Knowles SR, Shear NH. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol. 2003;2:278–99.PubMedGoogle Scholar
  16. Schneck J, Fagot J-P, Sekula P, et al. Effects of treatments of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study of patients included in the prospective EuroSCAR study. J Am Acad Dermatol. 2008;58:33–40.CrossRefPubMedGoogle Scholar
  17. Stern RS, Chan HL. Usefulness of case report literature in determining drugs responsible for toxic epidermal necrolysis. J Am Acad Dermatol. 1989;21(2 pt. 1):317–22.CrossRefPubMedGoogle Scholar
  18. Vittrorio C, Mugha J. Anticonvulsant hypersensitivity syndrome. Arch Intern Med. 1995;155:2285–90.CrossRefGoogle Scholar
  19. Wong CH, Haw-Chong C, Shanker P, et al. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am. 2003;85:1454–60.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Steven R. Mays
    • 1
    Email author
  • Sharon R. Hymes
    • 2
  • Katherine C. Cole
    • 3
  • Henry M. Kuerer
    • 3
  1. 1.Department of DermatologyThe University of Texas Medical School at HoustonHoustonUSA
  2. 2.Department of DermatologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Department of Surgical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations